NCI Announcement of Interest in Supporting Immuno-Oncology Research and Career Development through NIH Parent PA-18-591, "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)"

---

Notice Number: NOT-CA-18-056

Key Dates
Release Date: April 3, 2018

Related Announcements
PA-18-591

Issued by
National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) participates in the National Institutes of Health (NIH) Parent Program Announcement PA-18-591, "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)." Through this Notice, the NCI announces that currently funded NCI Paul Calabresi Career Development Award for Clinical Oncology (K12) programs are welcome to apply for supplemental funds supporting additional K12 scholars conducting career development activities in immuno-oncology related areas, including but not limited to:

• Combinational therapies of immune modulators and other modalities;
• The development of resistance to immunotherapy;
• The identification of predictive immunotherapy biomarkers;
• Discovery of new checkpoints and checkpoint inhibitors, including small molecules for immunotherapy;
• The effect of mutational load, development of neoantigens, genetic or epigenetic evolution, or tumor heterogeneity on efficacy of immunotherapy; and
• Unexpected toxicities of immunotherapy.

NCI will accept applications for supplemental funds to support additional K12 Scholars conducting training in immuno-oncology through the NIH Parent Program Announcement PA-18-591 "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)." Relevant Information about the NIH Parent Program Announcement PA-18-591, "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)," can be found at https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html.

All currently funded NCI K12 programs are eligible to apply. Both MD and PhD candidates are eligible as supplemental Scholars. Each program may request to appoint up to three new mentors with expertise in immuno-oncology. Their biosketches should be included in the application.

Each program can apply for additional funds to support one supplemental K12 Scholar for 3 years. Programs may refill the supplemental slot if the K12 Scholar initially appointed does not utilize the full 3 years of funding. Allowable costs for salary and research-related expenses for this supplemental appointment are the same as those described in PAR-18-292. NCI plans to make five to 10 supplemental awards.

Application Page Limit: Scholar eligibility statement is limited to 1 page. The research experience plan for this supplemental Scholar is limited to 2 pages. Other page limits are as found in the Table of Page Limits (https://grants.nih.gov/grants/how-to-apply-application-guide/format-and-write/page-limits.htm#train).

Application Due Date: May 16, 2018

Review and Selection: Applications will be administratively reviewed. Selections will be made in July 2018 based on the strength of the mentor pool in immuno-oncology, the qualifications of the candidate, the merits of the research experience plan, and the amount of available funds.

Inquiries

Please direct all inquiries to:

Mark Damico, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5630
Email: mark.damico@nih.gov

Ming Lei, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5630
Email: ming.lei@nih.gov

---

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

---